On Monday, Nov. 10, the U.S. Department of Health and Human Services announced that the Food and Drug Administration would eliminate the “boxed labeling” requirement for estrogen products.
The “black box warning,” as it’s commonly called, is part of the fallout from a press conference that occurred more than 20 years ago, announcing the findings of the Women’s Health Initiative (WHI). It’s also been the subject of a half-century-long push and pull with the federal government.
Make no mistake, this has been a longstanding demand—it’s neither new nor MAHA-driven. Doctors and scientists have made the case for its removal since the start to no avail, arguing the data from the WHI—the largest, most expensive, and only randomized placebo-controlled study of post-menopausal women—never supported putting it there in the first place.
The FDA’s reversal of the labeling requirement is a major win for evidence-based medicine. Now it’s up to us to responsibly inform women of their choices.











